Kif1a-associated neurological disorder (KAND) is a rare and severe neurodegenerative condition. It is caused by mutations in Kif1a – a neuronal molecular protein. One hallmark of this disorder is early life epilepsy which can exasperate or cause detriments to brian development. The goal of this study is to better understand KIF1a and identify FDA approved drugs that can decrease seizure activity by testing patient iPSC derivied brain organoids. By doing so, we hope to alleviate a major debilitating clinical feature of KAND.